Tagged with B

France Elizabeth Ducottet, the 5th generation CEO of French family company Thuasne, shares the group’s history and goes on to explain how it has evolved into a professionally and innovatively driven family business, leading the European wearable device sector.   We conceive, develop, patent, manufacture, market, and distribute all of our…

Korea Dr Kyung Sook Kim, CEO of Corestem, explains how her company has been pioneering the Korean stem cell industry since its foundation in 2003. She also discusses reimbursement and regulation issues that come along this expensive and complex technology and shows how stem cell therapies can be better included in…

Egypt On Tuesday, February 12th, Pharmaboardroom attended a breakfast event hosted by the British Egyptian Business Association (BEBA) on competition law at the Cairo Semiramis Intercontinental Hotel. The theme for the event was competition law and its application in the Egyptian market, with the topic being introduced through a speech by…

Egypt Tarek Tawfik, managing director of AmCham Egypt, explains how Egypt’s latest economic reforms have transformed the country into an attractive destination for foreign investors. He highlights the special role of Egypt in the region and shows how the public and the private sectors are collaborating to achieve economic growth.  …

China Harbour BioMed is a fast-growing global biotech company with facilities in Rotterdam, Boston and Shanghai. The company is laser-focused on developing both proprietary and in-licensed immunological therapies using their state-of-the-art transgenic mice technology platforms, which it also licenses to other biotechs. CEO Dr. Jingsong Wang discusses the firm’s strategy, its…

China Tian Wee Ng, managing director (Asia-Pacific) for Pierre Fabre Medicament, shares insight on how the business has evolved in the region, moving from an opportunistic approach to a more strategic one, since his appointment in 2016. He also discusses the value of Pierre Fabre’s oncology portfolio for the region and…

China Rogers Luo Yongqing, global VP and general manager (China), Gilead Sciences, shares the key accomplishments of Gilead in China with six innovative products approved in just 15 months; the strategic significance of Gilead China as the newest affiliate for Gilead globally; and their commitment to maximizing patient access in China…

China While others have failed during the last 30 years, Hua Medicine has finally succeeded in developing a breakthrough diabetes treatment controlling blood glucose levels by taking a novel approach and modulating the glucokinase enzyme. The company is now applying the same principles to develop treatments for CNS disorders. Hua Medicine’s…

Egypt Nadia Lamloum, executive director of the British Egyptian Business Association (BEBA), discusses the role of her institution and the investment opportunities that Egypt has to offer, as well as the initiatives being undertaken to form partnerships between industry, government officials and regulatory bodies.   Due to Egypt’s rising population, the demand…

Korea Dr Jin San-Yoo, president and CEO of PharmAbcine, lifts the lid on the company’s combination therapy with MSD’s blockbuster oncology treatment Keytruda. Dr Yoo explains the rationale behind his decision to base his clinical trials in Australia and provides his assessment of the future for oncology drug development in the…

China China’s regulator approved a biosimilar version of Roche’s Rituxan this week, the first such drug ever to be given the green light in the country. With numerous other biological copycats of blockbuster drugs in development, potentially difficult times lie ahead for Roche and other Big Pharma firms in China.  …

Japan Already established as one of the world’s leading markets for innovative and patented drugs, Japan is set to grow rapidly in 2019, partly as a result of a dramatic uptake in generics and biosimilars.   Japan’s pharmaceutical industry has long centred on strong innovation and patented drugs, but we are…